局限期小细胞肺癌并发尿毒症患者化疗疗效及血药浓度变化1例报告及文献复习

doi:10.13481/j.1671-587X.20250625

Abstract

Abstract:

Limited-stage small cell lung cancer （SCLC） is a highly malignant and rapidly progressing neuroendocrine tumor， while uremia is a complication of the end-stage of chronic renal failure. The patients with SCLC complicated with uremia have poor treatment tolerance， limited options for anti-tumor treatment regimens， and great difficulty in diagnosis and treatment. This study analyzed one case of a 69-year-old male patient with limited-stage SCLC complicated with uremia （with a history of regular hemodialysis， 3 times per week）， to discuss his first-line treatment regimen， efficacy， and the impact of hemodialysis on the plasma concentrations of the anti-tumor drugs， and reviewed the relevant literature to provide a reference for the treatment of similar patients. The patient was admitted to the hospital due to “cough and hemoptysis for half a month” and was diagnosed with limited-stage SCLC stage ⅢA （T2aN2M0） by computed tomography （CT） and lung puncture biopsy. After discussion by the multi-disciplinary treatment （MDT） team， the patient received 6 cycles of Etoposide（VP-16） + carboplatin chemotherapy combined with adebrelimab immunotherapy， followed by sequential adebrelimab maintenance therapy. The efficacy was evaluated as partial response （PR） and the response is ongoing. During the treatment， level 4 hemoglobin decrease， level 3 neutropenia， and level 2 leukopenia occurred， which were alleviated after symptomatic treatment. The blood concentration monitoring results showed that the plasma concentrations of etoposide and carboplatin increased rapidly during drug infusion， and gradually decreased after the end of infusion. Hemodialysis could rapidly reduce the plasma concentration of carboplatin， but had no significant effect on the plasma concentration of etoposide. Therefore， the immunotherapy combined with reduced-dose chemotherapy regimen is safe and effective for this type of patient. Plasma drug concentration monitoring can be used to observe drug metabolism， but the optimal monitoring time points and clinical value need further study and validation.

Key words: Small cell lung cancer, Uremia, Hemodialysis, Blood concentration, Chemotherapy, Therapeutic effect

CLC Number:

R734.2

Lei TANG,Peinan LIN,Ling ZHANG,Haiyan XU,Fengchun ZHANG. Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review[J].Journal of Jilin University(Medicine Edition), 2025, 51(6): 1687-1694.

Figures/Tables 5

Fig. 1

Fig. 2

Fig. 3

Tab.1

Tab.2

References 28

[1]	MEGYESFALVI Z， GAY C M， POPPER H， et al. Clinical insights into small cell lung cancer： Tumor heterogeneity， diagnosis， therapy， and future directions［J］. CA Cancer J Clin， 2023， 73（6）： 620-652.
[2]	MAISONNEUVE P， AGODOA L， GELLERT R， et al. Cancer in patients on dialysis for end-stage renal disease： an international collaborative study［J］. Lancet， 1999， 354（9173）： 93-99.
[3]	TU H K， WEN C P， TSAI S P， et al. Cancer risk associated with chronic diseases and disease markers： prospective cohort study［J］. BMJ， 2018， 360： k134.
[4]	甘良英，左力. 血液透析人群中消除丙型肝炎病毒感染［J］. 临床肝胆病杂志， 2024， 40（4）： 659-664.
[5]	DON Y， PYO L， MI L， et al. Cancer in Korean patients with end-stage renal disease： a 7-year follow-up［J］. PLoS One， 2017， 12（7）： e0178649.
[6]	刘慧洁. 维持血液透析患者肿瘤发生及其相关因素的探讨［J］. 中华肿瘤防治杂志， 2018， 25（S2）： 85， 87.
[7]	WANG L M， XU X， ZHANG M， et al. Prevalence of chronic kidney disease in China： results from the sixth China chronic disease and risk factor surveillance［J］. JAMA Intern Med， 2023， 183（4）： 298-310.
[8]	THAI A A， SOLOMON B J， SEQUIST L V， et al. Lung cancer［J］. Lancet， 2021， 398（10299）： 535-554.
[9]	MEIJER J J， LEONETTI A， AIRÒ G， et al. Small cell lung cancer： Novel treatments beyond immunotherapy［J］. Semin Cancer Biol， 2022， 86（Pt 2）： 376-385.
[10]	LEE J H， SAXENA A， GIACCONE G. Advancements in small cell lung cancer［J］. Semin Cancer Biol， 2023， 93： 123-128.
[11]	TAKADA M， FUKUOKA M， KAWAHARA M， et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer： results of the Japan Clinical Oncology Group Study 9104［J］. J Clin Oncol， 2002， 20（14）： 3054-3060.
[12]	李雪芹，张凡，李倩. 免疫检查点抑制剂同步化疗治疗非小细胞肺癌效果及对患者肿瘤标志物和免疫细胞水平的影响［J］. 肿瘤研究与临床， 2023， 35（2）： 99-103.
[13]	LAHIRI A， MAJI A， POTDAR P D， et al. Lung cancer immunotherapy： progress， pitfalls， and promises［J］. Mol Cancer， 2023， 22（1）： 40.
[14]	PETTY W J， PAZ-ARES L. Emerging strategies for the treatment of small cell lung cancer： a review［J］. JAMA Oncol， 2023， 9（3）： 419-429.
[15]	闫焱，焦碧航，周昆，等. 基线BMI与免疫检查点抑制剂治疗晚期非小细胞肺癌疗效的关系［J］. 郑州大学学报（医学版）， 2023， 58（3）： 373-377.
[16]	ZHANG C Y， XU C， GAO X Y， et al. Platinum-based drugs for cancer therapy and anti-tumor strategies［J］. Theranostics， 2022， 12（5）： 2115-2132.
[17]	VOLAREVIC V， DJOKOVIC B， JANKOVIC M G， et al. Molecular mechanisms of cisplatin-induced nephrotoxicity： a balance on the knife edge between renoprotection and tumor toxicity［J］. J Biomed Sci， 2019， 26（1）： 25.
[18]	ZRAIK I M， HEß-BUSCH Y. Management of chemotherapy side effects and their long-term sequelae［J］. Urologe A， 2021， 60（7）： 862-871.
[19]	CALVERT A H， NEWELL D R， GUMBRELL L A， et al. Carboplatin dosage： prospective evaluation of a simple formula based on renal function［J］. J Clin Oncol， 2023， 41（28）： 4453-4454.
[20]	JANUS N， THARIAT J， BOULANGER H， et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients［J］. Ann Oncol， 2010， 21（7）： 1395-1403.
[21]	LE T T， WU M L， LEE J H， et al. Etoposide promotes DNA loop trapping and barrier formation by topoisomerase Ⅱ［J］. Nat Chem Biol， 2023， 19（5）： 641-650.
[22]	LIU S V， RECK M， MANSFIELD A S， et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab， carboplatin， and etoposide （IMpower133）［J］. J Clin Oncol， 2021， 39（6）： 619-630.
[23]	DOSTÁL Z， BUCHTÍKOVÁ J， MANDRLA J， et al. On the mechanism of miR-29b enhancement of etoposide toxicity in vitro ［J］. Sci Rep， 2024， 14（1）： 19880.
[24]	WANG J， ZHOU C C， YAO W X， et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer （CAPSTONE-1）： a multicentre， randomised， double-blind， placebo-controlled， phase 3 trial［J］. Lancet Oncol， 2022， 23（6）： 739-747.
[25]	CHENG Y， SPIGEL D R， CHO B C， et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer［J］. N Engl J Med， 2024， 391（14）： 1313-1327.
[26]	高和，纪树国，王峰，等. 大剂量卡铂化疗的药代动力学［J］. 天津医药， 1998， 26（1）： 32-34.
[27]	陆基宗，许英华，贺晴，等. 高效液相色谱法测定白血病人依托泊苷血药浓度及其药物动力学研究［J］. 中国现代应用药学， 2001， 18（1）： 37-39.
[28]	QIN Z Y， REN G H， YUAN J J， et al. Systemic evaluation on the pharmacokinetics of platinum-based anticancer drugs from animal to cell level： based on total platinum and intact drugs［J］. Front Pharmacol， 2020， 10： 1485.

Time	VP-16		Carboplatin
Time	Description	Value[ρ_B/(mg·L^-1)]	Description	Value[ρ_B/(mg·L^-1)]
Day 1
07:30	Before starting the medication	<0.02
08:30	1 h and before the end of medication	13.69	Before starting the medication	0.00
09:30	1 h after the end of the medication	9.02	1 h and before the end of medication	3.84
10:30	2 h after the end of the medication	8.34	1 h after the end of the medication	2.93
11:30	3 hours after the end of the medication	7.50	2 h after the end of the medication	2.85
12:30	4 h after the end of the medication and dialysis begins	6.86	3 h after the end of the medication and dialysis begins	2.70
13:30	5 h after the end of medication, and 1 hour after the start of dialysis	5.57	4 h after the end of medication, and 1 hour after the start of dialysis	0.31
14:30	6 h after the end of medication, and 2 hours after the start of dialysis	4.82	5 h after the end of medication, and 2 hours after the start of dialysis	0.27
15:30	7 h after the end of medication, and 3 h after the start of dialysis	4.38	6 h after the end of medication, and 3 h after the start of dialysis	0.27
16:30	8 h after the end of medication, 4 h after the start of dialysis, and the end of dialysis	3.65	7 h after the end of medication, 4 h after the start of dialysis, and the end of dialysis	0.28
17:30	-	-	8 h after the end of medication and 1 hour after the end of dialysis	0.26
18:30	10 h after the end of medication and 2 h after the end of dialysis	3.32	9 h after the end of medication and 2 hours after the end of dialysis	0.26
Day 2
08:30	24 h after the end of medication and 16 h after the end of dialysis	1.76	-	-
09:30	-	-	24 h after the end of medication and 17 h after the end of dialysis	0.22
Day 3
07:30	48 h after the end of VP-16	0.39	-	-
08:30	-	-	48 h after the end of carboplatin	0.21

Adverse event	Base line	After treatment
ECOG PS	1.00	1.00
Fatigue (Grade)	1.00	3.00
Vomiting (Grade)	0	3.00
WBC (×10⁹ L^-1)	5.48	2.13
Neu (×10⁹ L^-1)	3.64	0.66
HGB (g·L^-1)	124.00	55.00
PLT (×10⁹ L^-1)	181.00	105.00
TBil (μmol·L^-1)	5.40	4.90
DBil (μmol·L^-1)	0.90	1.30
ALT (U·L^-1)	5.00	7.00
AST (U·L^-1)	18.00	14.00
ALB (g·L^-1)	44.6	37.20
ALP (U·L^-1)	98.00	72.00
BUN (mmol·L^-1)	15.20	12.77
SCr (μmol·L^-1)	754.50	580.20
UA (μmol·L^-1)	282.30	192.40

Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 28

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Dongxin JIANG, Yunqian LI. Research progress in clinical diagnosis and treatment of oligodendroglioma [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 272-280.
[2]	Xingxiang WANG,Ying ZHAO,Qiaotong REN,Hefei WANG,Gang PU,Chun LI. Promotive effect of M2 macrophages on epithelial-mesenchymal transition and cisplatin resistance in non-small cell lung cancer A549 cells by regulating NF-κB signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 642-652.
[3]	Congcong BAI,Xianlei ZHOU,Zhi ZHANG,Shuang GAO,Xuemei ZHANG. Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 392-402.
[4]	Yang XUE,Yingxin RUAN,Tiekun YAN,Junya JIA,Shan LIN. Ameliorative effect of ACE2/Ang（1-7）/Mas axis on high-turover bone disease in uremic rats [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 26-33.
[5]	Yuwei KANG,Wei YANG,Shijie MA,Wei ZHOU,Fei DENG. Levels of sICAM-1 and sVCAM-1 and activity of SOD in serum and their relationships with coronary artery calcification in patients with maintenance hemodialysis [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 812-818.
[6]	Ying ZHANG,Xianxun JIANG,Zhaohui WAN. Enhancement effect of TPX2 gene silencing on chemosensitivity of bladder cancer cell line T24/DDP to cisplatin and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 346-354.
[7]	Lihua WANG,Lan JIA,Haiyan CHEN,Bo YANG,Zhe WANG,Xueqing BI. Effect of tanshinone ⅡA on function of human umbilical vein endothelial cells after treated with uremic toxin [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 364-370.
[8]	Yumo LIU,Chunyue MIAO,Ling SHAN,Wanxia LIU,Yuling OUYANG,Feiyong JIA. Research progress in early start denver model for treatment of autism spectrum disorder [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 273-279.
[9]	Xiaohui WU,Fan YANG,Xinru GUO,Ke YUAN,Zongyi MA,Ting LIAN,Rajiv Kumar JHA. Effect of Orlistat combined with EZH2 inhibitor GSK126 on lipid metabolism reprogramming in pancreatic cancer cells [J]. Journal of Jilin University(Medicine Edition), 2023, 49(1): 55-66.
[10]	Jing ZHANG,Shaoheng WANG,Pengfei LIU,Lei. GUAN. Effects of continuous infusion of dexmedetomidine on lactate metabolism and postoperative recovery in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy [J]. Journal of Jilin University(Medicine Edition), 2022, 48(5): 1305-1313.
[11]	Chengyuan HE,Hongyu YANG,Yujing TAN,Hang SU,Hongshu LI,Chun LI. Expression of IL-17A in non-small cell lung cancer tissue and its regulation on VEGF expression via NF-κB signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1003-1009.
[12]	Qingxu LANG,Xueshuang NIU,Kaiwen YANG,Ren ZHANG,Siteng WANG, ZUMIRETIGULI·Wumaier,Zhenqi WANG. Effects of sodium butyrate combined with ionizing radiation on apoptosis of lung cancer A549 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 915-921.
[13]	Junjie HOU,Xuguang MI,Xiaonan LI,Xiaonan LI,Ying YANG,Xianzhuo JIANG,Ying ZHOU,Zhiqiang NI,Ningyi JIN,Yanqiu FANG. Treatment of advanced rectal cancer with rectovaginal fistula through bevacizumab combined with FOLFIRI regimen: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 790-795.
[14]	Junjie HOU,Xuguang MI,Xiaonan LI,Xiaonan LI,Ying YANG,Xianzhuo JIANG,Ying ZHOU,Zhiqiang NI,Ningyi JIN,Yanqiu FANG. Bronchopleural fistula complicated in treatment process of non-small cell lung cancer by bevacizumab combined with paclitaxel: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 513-517.
[15]	Yingjun REN, Hui ZHANG, Ying ZHOU. Inhibitory effects of centromere protein U knockdown on self-renewal, cisplatin resistance and Wnt/β-catenin signaling activity in cisplatin resistant ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 608-614.